SAFETY, EFFICACY AND QUALITY OF LIFE ASSESMENT IN PATIENTS WITH BPH TREATED WITH DALFAZ 2,5 MG. - OPEN MULTICENTRIC CLINIC STUDY SUMMARY
Article published in Urologia Polska 2000/53/2.

authors

Maciej Niemierko, Piotr Dobroński, Andrzej Borkowski: Katedra i Klinika Urologii AM w Warszawie
Kierownik Kliniki: prof. dr. hab. med. A. Borkowski

Objective. To confirm efficacy and safety of Dalfaz (alfuzosin) 2.5 mg tid in

treatment of Symptomatic BPH.

Material end methods. In the twelve weeks open, uncontrolled study 365

patients aged 45-65 were encompassed in 25 institutions in Poland.

Results. Statistical analysis revealed significant improvement of LUTS

evaluated by I-PSS and quality of life measured by AUA Quality of Life

questionnaire. This study confirmed efficacy and safety od Dalfaz 2.5 mg tid.

Beneficial therapeutic effect was observed after 4 weeks of treatment. Side effects

that resulted in withdrawal from the study occurred in 2.2% of patients.

Conclusions. Treatment of patients with BPH with Dalfaz 2.5 mg is effective

and safe. Therapeutic effect - measured by I-PSS and AUA QoL - is noted in

the early phase of treatment.

[1] Cavero, I. et al.: Adrenoceptor antagonist effects ofAlfuzosin in rabbits and dogs
lower urinary tract. Br. J. Pharmacol. 1985, 86,146.
[2] Duzendorfer, U.: Clinical experience: Symptomatic managment of BPH with te-
razosin. Urology. 1988, 37 (suppl.), 27-31.
[3] Gensterberg, T. et al.: Phenoxybenzamine reduces bladder outlet obstruction in
benign prostatic hyperplasia - a urodynamic investigation. Inves. Urol. 1980,18,
29-31.
[4] Hanecki, R.: Farmakologiczne leczenie łagodnego wzrostu gruczołu krokowego.
Nowa Med. 1996, 2, 8-11.
[5] Jardin, A. et al.: Alfuzosin for treatment of benign prostatic hypertrophy. Lan-
cet. 1991, 37, 1457-1461.
[6] Jardin, A.: Alfuzosin. In: Textbook of benign prostatic hyperplasia. ISIS Medical
Media, Oxford 1996, 295-307.
[7] Kirby, R. S. et al.: Prazosin in the treatment of prostatic obstruction. A placebo
controlled study. Br. J. Urol. 1987, 60,136-142.
[8] Martorana, G. et al.: Effects of short-term treatment with the alpha-1 blocker
alfuzosin on urodynamic presure/flow parameters in patients with benign prostatic
hyperplasia. Eur. Urol. 1997, 32, 47-53.
[9] Pelberg, S. et al.: Adrenergic response of bladder muscle in prostatic obstruction.
Its relation to detrusor instability. Urology 1982, 20, 524-527.
[10] Ramsay, J. W. et al.: A double-blind controlled trial of a new alpha blocking drug
in the treatment of bladder outlet obstruction. Br. J. Urol. 1985, 57, 657-659.